92Bio revives experimental T cell engager previously handed to Amgen
read at Endpoints ↗Neutral
92Bio, a small California biotech, announced it is bringing back an experimental T‑cell engager it originally created before transferring the program to Amgen.
The company said the candidate will now be developed internally and moved toward human studies, after years of inactivity under Amgen.
No details on timelines, regulatory filings or partnerships were provided, and the move reflects 92Bio’s strategy to revive its own pipeline assets.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “92Bio revives a T cell engager it had transferred to Amgen”
read at Endpoints ↗92 words · retrieved Jul 1
comments(0)
5-min edit window · permanent after that